Proteins and Peptides

9 December 2024

tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients

9 December 2024

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

8 December 2024

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

6 December 2024

Simcha Therapeutics Announces the Opening of Two Clinical Studies Exploring ST-067 in Hematological Indications

4 December 2024

Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

4 December 2024

AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M

3 December 2024

Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth

28 November 2024

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

28 November 2024

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

20 November 2024

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

20 November 2024

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

20 November 2024

ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 – The Liver Meeting®

18 November 2024

Lilly’s tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity

15 November 2024

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet’s Disease

14 November 2024

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks

13 November 2024

Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio

12 November 2024

Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications

9 November 2024

Radella Pharmaceuticals Announces Topline Data from the Phase 1a Study of MD-18, a First-In-Class Peptide Targeting PTP1B for Obesity

9 November 2024

Palleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

6 November 2024

Hanmi Unveils Novel Obesity Drug ‘HM17321’ : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

4 November 2024

Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes

4 November 2024

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024

4 November 2024

CinFina Pharma Presents Positive Phase 1 Study Results in Poster Session for CIN-109 and in Late-Breaking Poster for CIN-110, Demonstrating the Potential of Next-Generation Mechanisms at ObesityWeek® 2024

31 October 2024

Meitheal Pharmaceuticals Secures Exclusive Commercial Licensing Agreement for Three Biosimilars in the U.S.

31 October 2024

KITHER BIOTECH ANNOUNCES PHASE 1 CLINICAL STUDY OF KIT2014, A NOVEL INHALED PEPTIDE THERAPY FOR CYSTIC FIBROSIS

30 October 2024

Bitterroot Bio Completes Enrollment in Phase 1 First-in-Human Study of BRB-002 in Healthy Volunteers

30 October 2024

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

23 October 2024

AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study

22 October 2024

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024

21 October 2024

Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Nectin-4-Targeted Immunotherapy Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

PSMA-Targeted Therapy Pipeline Review

TSLP Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

FcRn Inhibitors Pipeline Review

GPC3-Targeted Immunotherapy Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Mesothelin-Targeted Immunotherapy Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases